Clinical trial
Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Solid…
NCT00104286 · SGX Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00104286 |
|---|---|
| Title | Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Solid Tumors |
| Official title | An Open-Label, Single-Arm, Phase I Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Subjects With an Advanced Solid Malignancy |
| Lead sponsor | SGX Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | Troxatyl™ (Cytotoxic Chemotherapeutic) |
| Enrollment | 50 |
| Start date | Jan 1, 2003 |
| Completion | Nov 1, 2005 |
| First posted | Feb 25, 2005 |
| Last update posted | Nov 3, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: